These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11535198)

  • 1. Numerical modelling of the perturbation of HIV-1 during combination anti-retroviral therapy.
    Gumel AB; Loewen TD; Shivakumar PN; Sahai BM; Yu P; Garba ML
    Comput Biol Med; 2001 Sep; 31(5):287-301. PubMed ID: 11535198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of HIV infection of CD4+ T cells.
    Perelson AS; Kirschner DE; De Boer R
    Math Biosci; 1993 Mar; 114(1):81-125. PubMed ID: 8096155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oscillatory viral dynamics in a delayed HIV pathogenesis model.
    Wang Y; Zhou Y; Wu J; Heffernan J
    Math Biosci; 2009 Jun; 219(2):104-12. PubMed ID: 19327371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-16 anti-HIV-1 therapy.
    Viglianti GA; Parada NA; Maciaszek JW; Kornfeld H; Center DM; Cruikshank WW
    Nat Med; 1997 Sep; 3(9):938. PubMed ID: 9288705
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV-1 dynamics in vivo.
    Ho DD
    J Biol Regul Homeost Agents; 1995; 9(3):76-7. PubMed ID: 8782010
    [No Abstract]   [Full Text] [Related]  

  • 6. Calculating the Expected Time to Eradicate HIV-1 Using a Markov Chain.
    Viswanath NC
    IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(1):60-67. PubMed ID: 28650822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
    Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
    J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.
    Schrager LK; D'Souza MP
    JAMA; 1998 Jul; 280(1):67-71. PubMed ID: 9660366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the virus-immune system interactions in the peripheral bloodstream of HIV infected individuals using a cellular automata model with considering the effects of antiretroviral therapy.
    Golpayegani GN; Jafari AH; Dabanloo NJ
    Technol Health Care; 2017; 25(1):59-88. PubMed ID: 27689554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodic multidrug therapy in a within-host virus model.
    Browne CJ; Pilyugin SS
    Bull Math Biol; 2012 Mar; 74(3):562-89. PubMed ID: 21822766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
    Sluis-Cremer N
    Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the immunopathogenesis of HIV-1 infection and the effect of multidrug therapy: the role of fusion inhibitors in HAART.
    Magombedze G; Garira W; Mwenje E
    Math Biosci Eng; 2008 Jul; 5(3):485-504. PubMed ID: 18616354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovering from the ravages HIV.
    Cohen J
    Science; 1997 Jul; 277(5322):33. PubMed ID: 9229769
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.